|
Amarillo Biosciences Announces Preliminary Results that Indicate Influenza-Like Illness Incidence Reduced from 71% to 43% in Vaccinated Patients Treated with Oral Interferon, Symptoms Also Lessened |
 |
 |
 |
|
Wednesday, 03 February 2010 11:29 |
|
Analysis of Australian Phase 2 Oral Interferon Clinical Trial Continuing
Amarillo, Texas, February 3, 2010 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced preliminary results indicating that, in a recently completed Phase 2 clinical trial conducted in Perth, Australia at the University of Western Australia with Professors David Smith and Manfred Beilharz as principal investigators, the rate of influenza-like illness was significantly (p=0.01) reduced from 71% to 43% in interferon-treated subjects who received Fluvax (an influenza vaccine) prior to the study, compared to subjects in the placebo group who were vaccinated.
|
|
Read more... [Amarillo Biosciences Announces Preliminary Results that Indicate Influenza-Like Illness Incidence Reduced from 71% to 43% in Vaccinated Patients Treated with Oral Interferon, Symptoms Also Lessened]
|
|
Amarillo Biosciences Issues Update on Australian Phase 2 Clinical Trial |
|
|
|
|
Thursday, 17 December 2009 13:11 |
|
Amarillo, Texas, December 17, 2009 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that its ongoing study of oral interferon as prevention/treatment of influenza and other respiratory illnesses in Perth, Australia is nearing completion. A total of 200 healthy volunteers were enrolled in this Phase 2 clinical trial to take oral interferon or placebo lozenges once daily for 16 weeks, followed by 4 weeks of post-treatment observation. The treatment phase of the study was successfully concluded in November with over 80% of the volunteers completing 16 weeks of study medication. All subjects are scheduled to complete the 4 weeks of post-treatment observation by the end of the year.
|
|
Last Updated on Thursday, 17 December 2009 13:34 |
|
Read more... [Amarillo Biosciences Issues Update on Australian Phase 2 Clinical Trial]
|
|
|
Amarillo Biosciences Comments on New Findings of H1N1 in Animals and Potential Effect on Human Infections |
|
|
|
|
Wednesday, 11 November 2009 00:00 |
|
Amarillo, Texas, November 11, 2009 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) reported that the American Veterinary Medical Association (AVMA) recently confirmed that a household cat in Iowa developed signs of respiratory infection caused by H1N1 influenza virus. The AVMA report adds cats to the growing list of animals, including ferrets, hogs (most recently in Indiana and Taiwan) and turkeys reported to be infected by H1N1 influenza virus.
|
|
Last Updated on Thursday, 10 December 2009 10:16 |
|
Read more... [Amarillo Biosciences Comments on New Findings of H1N1 in Animals and Potential Effect on Human Infections]
|
|
Amarillo Biosciences Reports on Research Supporting Use of Interferon |
|
|
|
|
Tuesday, 13 October 2009 15:44 |
|
Amarillo, Texas, October 9, 2009 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that Professor Dr. Otto Haller from the Department of Virology, Freiburg University, Germany and Professor Dr. Oliver Planz from the Friedrich Loeffler Institute, Tubingen, Germany gave two separate presentations on the efficacy of interferon to combat influenza. The presentations were made at the National Symposium for Zoonosis Research, held in Berlin, Germany October 7-8, 2009. Dr. Haller’s presentation was entitled, Interferons as emergency antiviral agents against highly pathogenic influenza A viruses: efficacy evaluation in animal transmission models, and Dr. Planz’s presentation was named H5N1 and swine-origin H1N1 influenza A viruses are susceptible to interferon type I treatment in vitro and in vivo.
|
|
Read more... [Amarillo Biosciences Reports on Research Supporting Use of Interferon]
|
|